These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12048134)

  • 1. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia.
    Noji Y; Higashikata T; Inazu A; Nohara A; Ueda K; Miyamoto S; Kajinami K; Takegoshi T; Koizumi J; Mabuchi H;
    Atherosclerosis; 2002 Jul; 163(1):157-64. PubMed ID: 12048134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.
    Harada-Shiba M; Arisaka O; Ohtake A; Okada T; Suganami H;
    J Atheroscler Thromb; 2016; 23(1):48-55. PubMed ID: 25891210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group.
    Kajinami K; Koizumi J; Ueda K; Miyamoto S; Takegoshi T; Mabuchi H
    Am J Cardiol; 2000 Jan; 85(2):178-83. PubMed ID: 10955373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe.
    Harada-Shiba M; Kastelein JJP; Hovingh GK; Ray KK; Ohtake A; Arisaka O; Ohta T; Okada T; Suganami H; Wiegman A
    J Atheroscler Thromb; 2018 May; 25(5):422-429. PubMed ID: 29187694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
    Larivière M; Lamarche B; Pirro M; Hogue JC; Bergeron J; Gagné C; Couture P
    Atherosclerosis; 2003 Mar; 167(1):97-104. PubMed ID: 12618273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study.
    Yoshitomi Y; Ishii T; Kaneki M; Tsujibayashi T; Sakurai S; Nagakura C; Miyauchi A
    J Atheroscler Thromb; 2006 Apr; 13(2):108-13. PubMed ID: 16733299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
    Nozue T; Michishita I; Ito Y; Hirano T
    J Atheroscler Thromb; 2008 Jun; 15(3):146-53. PubMed ID: 18603821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of cerivastatin in the treatment of heterozygous familial hypercholesterolemia.
    Mabuchi H; Koizumi J; Kajinami K
    Am J Cardiol; 1998 Aug; 82(4B):52J-55J. PubMed ID: 9737647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
    J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
    Mabuchi H; Fujita H; Michishita I; Takeda M; Kajinami K; Koizumi J; Takeda R; Takegoshi T; Wakasugi T; Ueda K
    Atherosclerosis; 1988 Aug; 72(2-3):183-8. PubMed ID: 3145745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
    Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
    Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
    Raal FJ; Marais AD; Klepack E; Lovalvo J; McLain R; Heinonen T
    Atherosclerosis; 2003 Dec; 171(2):273-9. PubMed ID: 14644397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
    Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
    PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
    Mabuchi H; Haba T; Tatami R; Miyamoto S; Sakai Y; Wakasugi T; Watanabe A; Koizumi J; Takeda R
    N Engl J Med; 1981 Aug; 305(9):478-82. PubMed ID: 7254297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.